{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T23:21:20Z","timestamp":1794525680070,"version":"4.9.1"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,2,27]],"date-time":"2023-02-27T00:00:00Z","timestamp":1677456000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,2,27]],"date-time":"2023-02-27T00:00:00Z","timestamp":1677456000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002839","name":"Charit\u00e9 - Universit\u00e4tsmedizin Berlin","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002839","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Headache Pain"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Clinical trials and real-world studies revealed a spectrum of response to CGRP(-receptor) monoclonal antibodies (mAbs) in migraine prophylaxis, ranging from no effect at all to total migraine freedom. In this study, we aimed to compare clinical characteristics between super-responders (SR) and non-responders (NR) to CGRP(-receptor) mAbs.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We performed a retrospective cohort study at the Headache Center, Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin. The definition of super-response was a\u2009\u2265\u200975% reduction in monthly headache days (MHD) in the third month after treatment initiation compared to the month prior to treatment begin (baseline). Non-response was defined as\u2009\u2264\u200925% reduction in MHD after three months of treatment with a CGRP-receptor mAb and subsequent three months of treatment with CGRP mAb, or vice versa. We collected demographic data, migraine disease characteristics, migraine symptoms during the attacks in both study groups (SR\/NR) as well as the general medical history. SR and NR were compared using Chi-square test for categorical variables, and t-test for continuous variables.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Between November 2018 and June 2022, <jats:italic>n<\/jats:italic>\u2009=\u2009260 patients with migraine received preventive treatment with CGRP(-receptor) mAbs and provided complete headache documentation for the baseline phase and the third treatment month. Among those, we identified <jats:italic>n<\/jats:italic>\u2009=\u200929 SR (11%) and <jats:italic>n<\/jats:italic>\u2009=\u200926 NR (10%). SR reported more often especially vomiting (SR <jats:italic>n<\/jats:italic>\u2009=\u200912\/25, 48% vs. NR <jats:italic>n<\/jats:italic>\u2009=\u20094\/22, 18%; <jats:italic>p<\/jats:italic>\u2009=\u20090.031) and typical migraine characteristics such as unilateral localization, pulsating character, photophobia and nausea. A subjective good response to triptans was significantly higher in SR (<jats:italic>n<\/jats:italic>\u2009=\u200926\/29, 90%) than in NR (<jats:italic>n<\/jats:italic>\u2009=\u200915\/25, 60%, <jats:italic>p<\/jats:italic>\u2009=\u20090.010). NR suffered more frequently from chronic migraine (NR <jats:italic>n<\/jats:italic>\u2009=\u200924\/26, 92% vs. SR <jats:italic>n<\/jats:italic>\u2009=\u200915\/29, 52%; <jats:italic>p<\/jats:italic>\u2009=\u20090.001), medication overuse headache (NR <jats:italic>n<\/jats:italic>\u2009=\u200914\/24, 58% versus SR <jats:italic>n<\/jats:italic>\u2009=\u20098\/29, 28%; <jats:italic>p<\/jats:italic>\u2009=\u20090.024), and concomitant depression (NR <jats:italic>n<\/jats:italic>\u2009=\u200917\/26, 65% vs. SR <jats:italic>n<\/jats:italic>\u2009=\u20098\/29, 28%; <jats:italic>p<\/jats:italic>\u2009=\u20090.005).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Several clinical parameters differ between SR and NR to prophylactic CGRP(-R) mAbs. A thorough clinical evaluation prior to treatment initiation might help to achieve a more personalized management in patients with migraine.\n<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s10194-023-01552-x","type":"journal-article","created":{"date-parts":[[2023,2,27]],"date-time":"2023-02-27T00:03:46Z","timestamp":1677456226000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":60,"title":["Clinical evaluation of super-responders vs. non-responders to CGRP(-receptor) monoclonal antibodies: a real-world experience"],"prefix":"10.1186","volume":"24","author":[{"given":"Bianca","family":"Raffaelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mira","family":"Fitzek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucas H.","family":"Overeem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Storch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Terhart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uwe","family":"Reuter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,2,27]]},"reference":[{"key":"1552_CR1","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/s41582-018-0003-1","volume":"14","author":"L Edvinsson","year":"2018","unstructured":"Edvinsson L, Haanes KA, Warfvinge K, Krause DN (2018) CGRP as the target of new migraine therapies - successful translation from bench to clinic. Nat Rev Neurol 14:338\u2013350. https:\/\/doi.org\/10.1038\/s41582-018-0003-1","journal-title":"Nat Rev Neurol"},{"key":"1552_CR2","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1080\/14712598.2019.1671350","volume":"19","author":"B Raffaelli","year":"2019","unstructured":"Raffaelli B, Neeb L, Reuter U (2019) Monoclonal antibodies for the prevention of migraine. Expert Opin Biol Ther 19:1307\u20131317. https:\/\/doi.org\/10.1080\/14712598.2019.1671350","journal-title":"Expert Opin Biol Ther"},{"key":"1552_CR3","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1056\/NEJMoa1705848","volume":"377","author":"PJ Goadsby","year":"2017","unstructured":"Goadsby PJ, Reuter U, Hallstr\u00f6m Y, Broessner G, Bonner JH, Zhang F, Sapra S, Picard H, Mikol DD, Lenz RA (2017) A controlled trial of erenumab for episodic migraine. N Engl J Med 377:2123\u20132132. https:\/\/doi.org\/10.1056\/NEJMoa1705848","journal-title":"N Engl J Med"},{"key":"1552_CR4","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1177\/0333102418759786","volume":"38","author":"DW Dodick","year":"2018","unstructured":"Dodick DW, Ashina M, Brandes JL, Kudrow D, Lanteri-Minet M, Osipova V, Palmer K, Picard H, Mikol DD, Lenz RA (2018) ARISE: a phase 3 randomized trial of erenumab for episodic migraine. Cephalalgia 38:1026\u20131037. https:\/\/doi.org\/10.1177\/0333102418759786","journal-title":"Cephalalgia"},{"key":"1552_CR5","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/S1474-4422(17)30083-2","volume":"16","author":"S Tepper","year":"2017","unstructured":"Tepper S, Ashina M, Reuter U, Brandes JL, Dole\u017eil D, Silberstein S, Winner P, Leonardi D, Mikol D, Lenz R (2017) Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial. The Lancet Neurology 16:425\u2013434. https:\/\/doi.org\/10.1016\/S1474-4422(17)30083-2","journal-title":"The Lancet Neurology"},{"key":"1552_CR6","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1001\/jamaneurol.2017.3859","volume":"75","author":"V Skljarevski","year":"2018","unstructured":"Skljarevski V, Oakes TM, Zhang Q, Ferguson MB, Martinez J, Camporeale A, Johnson KW, Shan Q, Carter J, Schacht A et al (2018) Effect of different doses of galcanezumab vs placebo for episodic migraine prevention: a randomized clinical trial. JAMA Neurol 75:187\u2013193. https:\/\/doi.org\/10.1001\/jamaneurol.2017.3859","journal-title":"JAMA Neurol"},{"key":"1552_CR7","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1001\/jamaneurol.2018.1212","volume":"75","author":"VL Stauffer","year":"2018","unstructured":"Stauffer VL, Dodick DW, Zhang Q, Carter JN, Ailani J, Conley RR (2018) Evaluation of galcanezumab for the prevention of episodic migraine: the EVOLVE-1 randomized clinical trial. JAMA Neurol 75:1080\u20131088. https:\/\/doi.org\/10.1001\/jamaneurol.2018.1212","journal-title":"JAMA Neurol"},{"key":"1552_CR8","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1001\/jama.2018.4853","volume":"319","author":"DW Dodick","year":"2018","unstructured":"Dodick DW, Silberstein SD, Bigal ME, Yeung PP, Goadsby PJ, Blankenbiller T, Grozinski-Wolff M, Yang R, Ma Y, Aycardi E (2018) Effect of fremanezumab compared with placebo for prevention of episodic migraine: a randomized clinical trial. JAMA 319:1999\u20132008. https:\/\/doi.org\/10.1001\/jama.2018.4853","journal-title":"JAMA"},{"key":"1552_CR9","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1056\/NEJMoa1709038","volume":"377","author":"SD Silberstein","year":"2017","unstructured":"Silberstein SD, Dodick DW, Bigal ME, Yeung PP, Goadsby PJ, Blankenbiller T, Grozinski-Wolff M, Yang R, Ma Y, Aycardi E (2017) Fremanezumab for the preventive treatment of chronic migraine. N Engl J Med 377:2113\u20132122. https:\/\/doi.org\/10.1056\/NEJMoa1709038","journal-title":"N Engl J Med"},{"key":"1552_CR10","doi-asserted-by":"publisher","first-page":"e2211","DOI":"10.1212\/WNL.0000000000006640","volume":"91","author":"HC Detke","year":"2018","unstructured":"Detke HC, Goadsby PJ, Wang S, Friedman DI, Selzler KJ, Aurora SK (2018) Galcanezumab in chronic migraine: the randomized, double-blind, placebo-controlled REGAIN study. Neurology 91:e2211\u2013e2221. https:\/\/doi.org\/10.1212\/WNL.0000000000006640","journal-title":"Neurology"},{"key":"1552_CR11","doi-asserted-by":"publisher","first-page":"2280","DOI":"10.1016\/S0140-6736(18)32534-0","volume":"392","author":"U Reuter","year":"2018","unstructured":"Reuter U, Goadsby PJ, Lanteri-Minet M, Wen S, Hours-Zesiger P, Ferrari MD, Klatt J (2018) Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study. Lancet 392:2280\u20132287. https:\/\/doi.org\/10.1016\/S0140-6736(18)32534-0","journal-title":"Lancet"},{"key":"1552_CR12","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1016\/S0140-6736(19)31946-4","volume":"394","author":"MD Ferrari","year":"2019","unstructured":"Ferrari MD, Diener HC, Ning X, Galic M, Cohen JM, Yang R, Mueller M, Ahn AH, Schwartz YC, Grozinski-Wolff M et al (2019) Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial. Lancet 394:1030\u20131040. https:\/\/doi.org\/10.1016\/S0140-6736(19)31946-4","journal-title":"Lancet"},{"key":"1552_CR13","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1016\/S1474-4422(20)30279-9","volume":"19","author":"WM Mulleners","year":"2020","unstructured":"Mulleners WM, Kim B-K, L\u00e1inez MJA, Lanteri-Minet M, Pozo-Rosich P, Wang S, Tockhorn-Heidenreich A, Aurora SK, Nichols RM, Yunes-Medina L et al (2020) Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-controlled, phase 3b trial. Lancet Neurol 19:814\u2013825. https:\/\/doi.org\/10.1016\/S1474-4422(20)30279-9","journal-title":"Lancet Neurol"},{"key":"1552_CR14","doi-asserted-by":"publisher","first-page":"2026","DOI":"10.1111\/head.13929","volume":"60","author":"G Broessner","year":"2020","unstructured":"Broessner G, Reuter U, Bonner JH, Dodick DW, Hallstr\u00f6m Y, Picard H, Zhang F, Lenz RA, Klatt J, Mikol DD (2020) The Spectrum of response to erenumab in patients with episodic migraine and subgroup analysis of patients achieving \u226550%, \u226575%, and 100% response. Headache 60:2026\u20132040. https:\/\/doi.org\/10.1111\/head.13929","journal-title":"Headache"},{"key":"1552_CR15","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s10194-022-01433-9","volume":"23","author":"CK Cullum","year":"2022","unstructured":"Cullum CK, Do TP, Ashina M, Bendtsen L, Hugger SS, Iljazi A, Gusatovic J, Snellman J, Lopez-Lopez C, Ashina H et al (2022) Real-world long-term efficacy and safety of erenumab in adults with chronic migraine: a 52-week, single-center, prospective, observational study. J Headache Pain 23:61. https:\/\/doi.org\/10.1186\/s10194-022-01433-9","journal-title":"J Headache Pain"},{"key":"1552_CR16","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1111\/ene.15197","volume":"29","author":"F Vernieri","year":"2022","unstructured":"Vernieri F, Altamura C, Brunelli N, Costa CM, Aurilia C, Egeo G, Fofi L, Favoni V, Lovati C, Bertuzzo D et al (2022) Rapid response to galcanezumab and predictive factors in chronic migraine patients: a 3-month observational, longitudinal, cohort, multicenter, Italian real-life study. Eur J Neurol 29:1198\u20131208. https:\/\/doi.org\/10.1111\/ene.15197","journal-title":"Eur J Neurol"},{"key":"1552_CR17","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1111\/head.14032","volume":"61","author":"P Barbanti","year":"2021","unstructured":"Barbanti P, Aurilia C, Egeo G, Fofi L, Cevoli S, Colombo B, Filippi M, Frediani F, Bono F, Grazzi L et al (2021) Erenumab in the prevention of high-frequency episodic and chronic migraine: Erenumab in Real Life in Italy (EARLY), the first Italian multicenter, prospective real-life study. Headache 61:363\u2013372. https:\/\/doi.org\/10.1111\/head.14032","journal-title":"Headache"},{"key":"1552_CR18","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1111\/head.14194","volume":"61","author":"P Barbanti","year":"2021","unstructured":"Barbanti P, Aurilia C, Cevoli S, Egeo G, Fofi L, Messina R, Salerno A, Torelli P, Albanese M, Carnevale A et al (2021) Long-term (48 weeks) effectiveness, safety, and tolerability of erenumab in the prevention of high-frequency episodic and chronic migraine in a real world: results of the EARLY 2 study. Headache 61:1351\u20131363. https:\/\/doi.org\/10.1111\/head.14194","journal-title":"Headache"},{"key":"1552_CR19","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1186\/s10194-022-01498-6","volume":"23","author":"P Barbanti","year":"2022","unstructured":"Barbanti P, Egeo G, Aurilia C, Altamura C, d\u2019Onofrio F, Finocchi C, Albanese M, Aguggia M, Rao R, Zucco M et al (2022) Predictors of response to anti-CGRP monoclonal antibodies: a 24-week, multicenter, prospective study on 864 migraine patients. J Headache Pain 23:138. https:\/\/doi.org\/10.1186\/s10194-022-01498-6","journal-title":"J Headache Pain"},{"key":"1552_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s10194-020-01213-3","volume":"22","author":"I Frattale","year":"2021","unstructured":"Frattale I, Caponnetto V, Casalena A, Assetta M, Maddestra M, Marzoli F, Affaitati G, Giamberardino MA, Viola S, Gabriele A et al (2021) Association between response to triptans and response to erenumab: real-life data. J Headache Pain 22:1. https:\/\/doi.org\/10.1186\/s10194-020-01213-3","journal-title":"J Headache Pain"},{"key":"1552_CR21","doi-asserted-by":"publisher","first-page":"895476","DOI":"10.3389\/fneur.2022.895476","volume":"13","author":"M Nowaczewska","year":"2022","unstructured":"Nowaczewska M, Straburzy\u0144ski M, Waliszewska-Pros\u00f3\u0142 M, Meder G, Janiak-Kiszka J, Ka\u017amierczak W (2022) Cerebral blood flow and other predictors of responsiveness to erenumab and fremanezumab in migraine-a real-life study. Front Neurol 13:895476. https:\/\/doi.org\/10.3389\/fneur.2022.895476","journal-title":"Front Neurol"},{"key":"1552_CR22","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s10194-020-01143-0","volume":"21","author":"A Russo","year":"2020","unstructured":"Russo A, Silvestro M, Scotto di Clemente F, Trojsi F, Bisecco A, Bonavita S, Tessitore A, Tedeschi G (2020) Multidimensional assessment of the effects of erenumab in chronic migraine patients with previous unsuccessful preventive treatments: a comprehensive real-world experience. J Headache Pain 21:69. https:\/\/doi.org\/10.1186\/s10194-020-01143-0","journal-title":"J Headache Pain"},{"key":"1552_CR23","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1186\/s10194-021-01333-4","volume":"22","author":"S Bottiroli","year":"2021","unstructured":"Bottiroli S, De Icco R, Vaghi G, Pazzi S, Guaschino E, Allena M, Ghiotto N, Martinelli D, Tassorelli C, Sances G (2021) Psychological predictors of negative treatment outcome with erenumab in chronic migraine: data from an open label long-term prospective study. J Headache Pain 22:114. https:\/\/doi.org\/10.1186\/s10194-021-01333-4","journal-title":"J Headache Pain"},{"key":"1552_CR24","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/s40263-021-00893-y","volume":"36","author":"LF Iannone","year":"2022","unstructured":"Iannone LF, Fattori D, Benemei S, Chiarugi A, Geppetti P, De Cesaris F (2022) Long-term effectiveness of three anti-CGRP monoclonal antibodies in resistant chronic migraine patients based on the MIDAS score. CNS Drugs 36:191\u2013202. https:\/\/doi.org\/10.1007\/s40263-021-00893-y","journal-title":"CNS Drugs"},{"key":"1552_CR25","doi-asserted-by":"crossref","unstructured":"Zecca C, Cargnin S, Schankin C, Giannantoni NM, Viana M, Maraffi I, et al (2022) Clinic and genetic predictors in response to erenumab. Eur J Neurol 29(4):1209\u201317","DOI":"10.1111\/ene.15236"},{"key":"1552_CR26","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s10194-022-01396-x","volume":"23","author":"P Barbanti","year":"2022","unstructured":"Barbanti P, Egeo G, Aurilia C, d\u2019Onofrio F, Albanese M, Cetta I, Di Fiore P, Zucco M, Filippi M, Bono F et al (2022) Fremanezumab in the prevention of high-frequency episodic and chronic migraine: a 12-week, multicenter, real-life, cohort study (the FRIEND study). J Headache Pain 23:46. https:\/\/doi.org\/10.1186\/s10194-022-01396-x","journal-title":"J Headache Pain"},{"key":"1552_CR27","unstructured":"Nutzenbewertungsverfahren zum Wirkstoff Erenumab (Migr\u00e4ne-Prophylaxe) - Gemeinsamer Bundesausschuss https:\/\/www.g-ba.de\/bewertungsverfahren\/nutzenbewertung\/411\/#beschluesse."},{"key":"1552_CR28","unstructured":"Nutzenbewertungsverfahren zum Wirkstoff Galcanezumab (Migr\u00e4ne-Prophylaxe) - Gemeinsamer Bundesausschuss https:\/\/www.g-ba.de\/bewertungsverfahren\/nutzenbewertung\/450\/#beschluesse."},{"key":"1552_CR29","doi-asserted-by":"publisher","unstructured":"Nutzenbewertungsverfahren zum Wirkstoff Fremanezumab (Migr\u00e4ne-Prophylaxe)\u00a0- Gemeinsamer Bundesausschuss\u00a0in response to erenumab. Eur J Neurol 29:1209\u20131217. https:\/\/doi.org\/10.1111\/ene.15236 (https:\/\/www.g-ba.de\/bewertungsverfahren\/nutzenbewertung\/462\/#beschluesse.predictors)","DOI":"10.1111\/ene.15236"},{"key":"1552_CR30","doi-asserted-by":"publisher","unstructured":"Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018;38:1\u2013211. https:\/\/doi.org\/10.1177\/0333102417738202.","DOI":"10.1177\/0333102417738202"},{"key":"1552_CR31","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s10194-020-01130-5","volume":"21","author":"S Sacco","year":"2020","unstructured":"Sacco S, Braschinsky M, Ducros A, Lampl C, Little P, van den Brink AM, Pozo-Rosich P, Reuter U, de la Torre ER, Sanchez Del Rio M et al (2020) European headache federation consensus on the definition of resistant and refractory migraine: developed with the endorsement of the European Migraine & Headache Alliance (EMHA). J Headache Pain 21:76. https:\/\/doi.org\/10.1186\/s10194-020-01130-5","journal-title":"J Headache Pain"},{"key":"1552_CR32","doi-asserted-by":"publisher","first-page":"e2260","DOI":"10.1002\/brb3.2260","volume":"11","author":"C Baraldi","year":"2021","unstructured":"Baraldi C, Castro FL, Cainazzo MM, Pani L, Guerzoni S (2021) Predictors of response to erenumab after 12 months of treatment. Brain Behav 11:e2260. https:\/\/doi.org\/10.1002\/brb3.2260","journal-title":"Brain Behav"},{"key":"1552_CR33","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s10194-018-0927-2","volume":"19","author":"CE Christensen","year":"2018","unstructured":"Christensen CE, Younis S, Deen M, Khan S, Ghanizada H, Ashina M (2018) Migraine induction with calcitonin gene-related peptide in patients from erenumab trials. J Headache Pain 19:105. https:\/\/doi.org\/10.1186\/s10194-018-0927-2","journal-title":"J Headache Pain"},{"key":"1552_CR34","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/s10194-017-0811-5","volume":"18","author":"S Benemei","year":"2017","unstructured":"Benemei S, Cortese F, Labastida-Ram\u00edrez A, Marchese F, Pellesi L, Romoli M, Vollesen AL, Lampl C, Ashina M, School of Advanced Studies of the European Headache Federation (EHF-SAS) (2017) Triptans and CGRP blockade - impact on the cranial vasculature. J Headache Pain 18:103. https:\/\/doi.org\/10.1186\/s10194-017-0811-5","journal-title":"J Headache Pain"},{"key":"1552_CR35","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/1129-2377-15-7","volume":"15","author":"C Kageneck","year":"2014","unstructured":"Kageneck C, Nixdorf-Bergweiler BE, Messlinger K, Fischer MJ (2014) Release of CGRP from mouse brainstem slices indicates central inhibitory effect of triptans and kynurenate. J Headache Pain 15:7. https:\/\/doi.org\/10.1186\/1129-2377-15-7","journal-title":"J Headache Pain"},{"key":"1552_CR36","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1177\/0333102420949173","volume":"40","author":"BN Mason","year":"2020","unstructured":"Mason BN, Wattiez A-S, Balcziak LK, Kuburas A, Kutschke WJ, Russo AF (2020) Vascular actions of peripheral CGRP in migraine-like photophobia in mice. Cephalalgia 40:1585\u20131604. https:\/\/doi.org\/10.1177\/0333102420949173","journal-title":"Cephalalgia"},{"key":"1552_CR37","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000201332.10.1212\/WNL.0000000000201332","author":"J Ailani","year":"2022","unstructured":"Ailani J, Kaiser EA, Mathew PG, McAllister P, Russo AF, V\u00e9lez C, Ramajo AP, Abdrabboh A, Xu C, Rasmussen S et al (2022) Role of calcitonin gene-related peptide on the gastrointestinal symptoms of migraine-clinical considerations: a narrative review. Neurology. https:\/\/doi.org\/10.1212\/WNL.0000000000201332.10.1212\/WNL.0000000000201332","journal-title":"Neurology"},{"key":"1552_CR38","doi-asserted-by":"publisher","first-page":"251581632110266","DOI":"10.1177\/25158163211026646","volume":"4","author":"H Salem-Abdou","year":"2021","unstructured":"Salem-Abdou H, Simonyan D, Puymirat J (2021) Identification of predictors of response to erenumab in a cohort of patients with migraine. Cephalalgia Reports 4:25158163211026650. https:\/\/doi.org\/10.1177\/25158163211026646","journal-title":"Cephalalgia Reports"},{"key":"1552_CR39","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1177\/03331024211048765","volume":"42","author":"LH Overeem","year":"2022","unstructured":"Overeem LH, Peikert A, Hofacker MD, Kamm K, Ruscheweyh R, Gendolla A, Raffaelli B, Reuter U, Neeb L (2022) Effect of antibody switch in non-responders to a CGRP receptor antibody treatment in migraine: a multi-center retrospective cohort study. Cephalalgia 42:291\u2013301. https:\/\/doi.org\/10.1177\/03331024211048765","journal-title":"Cephalalgia"},{"key":"1552_CR40","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1002\/ana.26472","volume":"92","author":"A Alpuente","year":"2022","unstructured":"Alpuente A, Gallardo VJ, Asskour L, Caronna E, Torres-Ferrus M, Pozo-Rosich P (2022) Salivary CGRP and erenumab treatment response: towards precision medicine in migraine. Ann Neurol 92:846\u2013859. https:\/\/doi.org\/10.1002\/ana.26472","journal-title":"Ann Neurol"},{"key":"1552_CR41","doi-asserted-by":"publisher","first-page":"805334","DOI":"10.3389\/fneur.2021.805334","volume":"12","author":"J Schoenen","year":"2021","unstructured":"Schoenen J, Timmermans G, Nonis R, Manise M, Fumal A, G\u00e9rard P (2021) Erenumab for migraine prevention in a 1-year compassionate use program: efficacy, tolerability, and differences between clinical phenotypes. Front Neurol 12:805334. https:\/\/doi.org\/10.3389\/fneur.2021.805334","journal-title":"Front Neurol"},{"key":"1552_CR42","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s10194-022-01456-2","volume":"23","author":"M Lowe","year":"2022","unstructured":"Lowe M, Murray L, Tyagi A, Gorrie G, Miller S, Dani K, NHS Greater Glasgow and Clyde Headache Service (2022) Efficacy of erenumab and factors predicting response after 3\u00a0months in treatment resistant chronic migraine: a clinical service evaluation. J Headache Pain 23:86. https:\/\/doi.org\/10.1186\/s10194-022-01456-2","journal-title":"J Headache Pain"},{"key":"1552_CR43","doi-asserted-by":"publisher","first-page":"3092","DOI":"10.3390\/cells11193092","volume":"11","author":"R Greco","year":"2022","unstructured":"Greco R, Demartini C, Francavilla M, Zanaboni AM, Tassorelli C (2022) Antagonism of CGRP receptor: central and peripheral mechanisms and mediators in an animal model of chronic migraine. Cells 11:3092. https:\/\/doi.org\/10.3390\/cells11193092","journal-title":"Cells"},{"key":"1552_CR44","doi-asserted-by":"publisher","first-page":"1836","DOI":"10.1038\/s41598-018-19901-1","volume":"8","author":"G Munro","year":"2018","unstructured":"Munro G, Petersen S, Jansen-Olesen I, Olesen J (2018) A unique inbred rat strain with sustained cephalic hypersensitivity as a model of chronic migraine-like pain. Sci Rep 8:1836. https:\/\/doi.org\/10.1038\/s41598-018-19901-1","journal-title":"Sci Rep"},{"key":"1552_CR45","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1016\/j.neurol.2021.06.003","volume":"177","author":"L Edvinsson","year":"2021","unstructured":"Edvinsson L (2021) CGRP and migraine: from bench to bedside. Rev Neurol (Paris) 177:785\u2013790. https:\/\/doi.org\/10.1016\/j.neurol.2021.06.003","journal-title":"Rev Neurol (Paris)"},{"key":"1552_CR46","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1080\/13543784.2020.1811966","volume":"29","author":"C Rustichelli","year":"2020","unstructured":"Rustichelli C, Lo Castro F, Baraldi C, Ferrari A (2020) Targeting pituitary adenylate cyclase-activating polypeptide (PACAP) with monoclonal antibodies in migraine prevention: a brief review. Expert Opin Investig Drugs 29:1269\u20131275. https:\/\/doi.org\/10.1080\/13543784.2020.1811966","journal-title":"Expert Opin Investig Drugs"},{"key":"1552_CR47","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s10194-018-0850-6","volume":"19","author":"JA Waschek","year":"2018","unstructured":"Waschek JA, Baca SM, Akerman S (2018) PACAP and migraine headache: immunomodulation of neural circuits in autonomic ganglia and brain parenchyma. J Headache Pain 19:23. https:\/\/doi.org\/10.1186\/s10194-018-0850-6","journal-title":"J Headache Pain"},{"key":"1552_CR48","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1177\/0333102416684344","volume":"38","author":"H Ashina","year":"2018","unstructured":"Ashina H, Schytz HW, Ashina M (2018) CGRP in human models of primary headaches. Cephalalgia 38:353\u2013360. https:\/\/doi.org\/10.1177\/0333102416684344","journal-title":"Cephalalgia"},{"key":"1552_CR49","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1136\/jnnp.2009.192492","volume":"81","author":"DC Buse","year":"2010","unstructured":"Buse DC, Manack A, Serrano D, Turkel C, Lipton RB (2010) Sociodemographic and comorbidity profiles of chronic migraine and episodic migraine sufferers. J Neurol Neurosurg Psychiatry 81:428\u2013432. https:\/\/doi.org\/10.1136\/jnnp.2009.192492","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1552_CR50","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1111\/head.12195","volume":"54","author":"R Ruscheweyh","year":"2014","unstructured":"Ruscheweyh R, M\u00fcller M, Blum B, Straube A (2014) Correlation of headache frequency and psychosocial impairment in migraine: a cross-sectional study. Headache 54:861\u2013871. https:\/\/doi.org\/10.1111\/head.12195","journal-title":"Headache"},{"key":"1552_CR51","doi-asserted-by":"publisher","first-page":"656294","DOI":"10.3389\/fneur.2021.656294","volume":"12","author":"M Silvestro","year":"2021","unstructured":"Silvestro M, Tessitore A, Scotto di Clemente F, Battista G, Tedeschi G, Russo A (2021) Additive interaction between Onabotulinumtoxin-A and erenumab in patients with refractory migraine. Front Neurol 12:656294. https:\/\/doi.org\/10.3389\/fneur.2021.656294","journal-title":"Front Neurol"},{"key":"1552_CR52","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1136\/rapm-2018-100196","volume":"44","author":"M Barad","year":"2019","unstructured":"Barad M, Sturgeon JA, Fish S, Dexter F, Mackey S, Flood PD (2019) Response to BotulinumtoxinA in a migraine cohort with multiple comorbidities and widespread pain. Reg Anesth Pain Med 44:660\u2013668. https:\/\/doi.org\/10.1136\/rapm-2018-100196","journal-title":"Reg Anesth Pain Med"},{"key":"1552_CR53","doi-asserted-by":"publisher","first-page":"678","DOI":"10.3389\/fneur.2019.00678","volume":"10","author":"F Schiano di Cola","year":"2019","unstructured":"Schiano di Cola F, Caratozzolo S, Liberini P, Rao R, Padovani A (2019) Response predictors in chronic migraine: medication overuse and depressive symptoms negatively impact onabotulinumtoxin-a treatment. Front Neurol 10:678. https:\/\/doi.org\/10.3389\/fneur.2019.00678","journal-title":"Front Neurol"},{"key":"1552_CR54","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1111\/head.12941","volume":"56","author":"RB Lipton","year":"2016","unstructured":"Lipton RB, Munjal S, Buse DC, Fanning KM, Bennett A, Reed ML (2016) Predicting inadequate response to acute migraine medication: results from the American Migraine Prevalence and Prevention (AMPP) study. Headache 56:1635\u20131648. https:\/\/doi.org\/10.1111\/head.12941","journal-title":"Headache"},{"key":"1552_CR55","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1038\/nrneurol.2016.93","volume":"12","author":"A May","year":"2016","unstructured":"May A, Schulte LH (2016) Chronic migraine: risk factors, mechanisms and treatment. Nat Rev Neurol 12:455\u2013464. https:\/\/doi.org\/10.1038\/nrneurol.2016.93","journal-title":"Nat Rev Neurol"},{"key":"1552_CR56","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s10194-020-01102-9","volume":"21","author":"R Ornello","year":"2020","unstructured":"Ornello R, Casalena A, Frattale I, Gabriele A, Affaitati G, Giamberardino MA, Assetta M, Maddestra M, Marzoli F, Viola S et al (2020) Real-life data on the efficacy and safety of erenumab in the Abruzzo region, central Italy. J Headache Pain 21:32. https:\/\/doi.org\/10.1186\/s10194-020-01102-9","journal-title":"J Headache Pain"},{"key":"1552_CR57","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s10194-021-01328-1","volume":"22","author":"E Caronna","year":"2021","unstructured":"Caronna E, Gallardo VJ, Alpuente A, Torres-Ferrus M, Pozo-Rosich P (2021) Anti-CGRP monoclonal antibodies in chronic migraine with medication overuse: real-life effectiveness and predictors of response at 6 months. J Headache Pain 22:120. https:\/\/doi.org\/10.1186\/s10194-021-01328-1","journal-title":"J Headache Pain"},{"key":"1552_CR58","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1177\/0333102420942230","volume":"40","author":"R De Icco","year":"2020","unstructured":"De Icco R, Fiamingo G, Greco R, Bottiroli S, Demartini C, Zanaboni AM, Allena M, Guaschino E, Martinelli D, Putort\u00ec A et al (2020) Neurophysiological and biomolecular effects of erenumab in chronic migraine: an open label study. Cephalalgia 40:1336\u20131345. https:\/\/doi.org\/10.1177\/0333102420942230","journal-title":"Cephalalgia"},{"key":"1552_CR59","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s10194-022-01431-x","volume":"23","author":"S Sacco","year":"2022","unstructured":"Sacco S, Amin FM, Ashina M, Bendtsen L, Deligianni CI, Gil-Gouveia R, Katsarava Z, MaassenVanDenBrink A, Martelletti P, Mitsikostas D-D et al (2022) European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention - 2022 update. J Headache Pain 23:67. https:\/\/doi.org\/10.1186\/s10194-022-01431-x","journal-title":"J Headache Pain"}],"container-title":["The Journal of Headache and Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-023-01552-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s10194-023-01552-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-023-01552-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,27]],"date-time":"2023-02-27T00:03:53Z","timestamp":1677456233000},"score":1,"resource":{"primary":{"URL":"https:\/\/thejournalofheadacheandpain.biomedcentral.com\/articles\/10.1186\/s10194-023-01552-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,27]]},"references-count":59,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1552"],"URL":"https:\/\/doi.org\/10.1186\/s10194-023-01552-x","relation":{},"ISSN":["1129-2377"],"issn-type":[{"value":"1129-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,27]]},"assertion":[{"value":"7 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Charit\u00e9 Ethical Committee (EA1\/159\/22). Written informed consent was not required due to the retrospective nature of the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"R reports research grants from Novartis, and personal fees from Abbvie\/Allergan, Hormosan, Lilly, Novartis, and Teva. MF reports personal feed from TEVA. MT reports personal fees from TEVA. UR received honoraria for consulting and lectures from Amgen, Allergan, Abbvie, Eli Lilly, Lundbeck, Novartis, electroCore, Medscape, StreaMedUp, and Teva. UR received research funding from the German Federal Ministry of Education and Research and Novartis. The other authors have nothing to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"16"}}